A Munich-based biotechnology startup has closed a significant €30 million Series A funding round, marking a major milestone for the emerging field of microbiome-based cancer therapeutics. mbiomics GmbH is developing an innovative live bacterial product intended to work alongside existing immunotherapy drugs, potentially unlocking better treatment outcomes for patients with advanced melanoma who currently face limited options.
What Happened
mbiomics completed the final tranche of its Series A investment, bringing total capital raised to €30 million. The Munich-headquartered company plans to leverage this funding to advance its lead candidate toward human testing, with a Phase 1B clinical trial expected to launch in 2027. The biotech firm is targeting a specific gap in cancer treatment: enhancing the effectiveness of checkpoint inhibitors, a class of immunotherapy drugs that have revolutionized cancer care but don’t work for all patients.
Key Details
mbiomics’ approach represents a fascinating intersection of microbiology and oncology. Rather than developing a traditional small-molecule drug, the company is engineering live bacteria as a co-therapy designed to prime the immune system and amplify the body’s natural ability to recognize and destroy cancer cells. The strategy builds on growing scientific evidence that the gut microbiome plays a crucial role in immunotherapy response. By carefully selecting and cultivating specific bacterial strains, mbiomics aims to create a reproducible therapeutic that could be combined with existing checkpoint inhibitor treatments. The planned Phase 1B trial will test this hypothesis in melanoma patients, a disease where immunotherapy has shown promise but still leaves room for improvement in response rates.
What This Means for You
For cancer patients, this development could eventually translate into better survival rates and improved quality of life. The microbiome therapeutic space remains largely untapped, and success here could validate an entirely new category of cancer treatments that work synergistically with existing immunotherapies rather than replacing them. For investors watching the biotech sector, mbiomics represents a bet on the convergence of synthetic biology and precision medicine—two trends reshaping how companies approach disease. The funding also signals strong venture confidence in techbio startups solving real clinical challenges.
If the upcoming clinical trials demonstrate efficacy and safety, mbiomics could open doors for similar microbiome-based approaches across other cancer types and immune-related diseases. The next few years will be critical as the company navigates the regulatory pathway toward commercialization.
